To Meet Or Not To Meet? That Is CDER’s Question As Cmte. Cancellations Rise
Executive Summary
Clinical development and regulatory review are already full of uncertainties, but this year FDA introduced a new twist - canceling and postponing advisory committee meetings. Almost half of the scheduled meetings have not taken place, which may or may not be a bad sign for industry
You may also be interested in...
Will Vytorin Fallout Include ENHANCEd Reporting Requirements For All Trials?
Companies in heavily regulated industries such as pharmaceuticals often describe congressional investigations under the category of "headline risks": They produce a lot of bad press and a lot of work for the legal, public relations and lobbying arms, but their impact on the core functions of developing and selling drugs is limited
Will Vytorin Fallout Include ENHANCEd Reporting Requirements For All Trials?
Companies in heavily regulated industries such as pharmaceuticals often describe congressional investigations under the category of "headline risks": They produce a lot of bad press and a lot of work for the legal, public relations and lobbying arms, but their impact on the core functions of developing and selling drugs is limited
Firazyr advisory committee canceled
Jerini's hereditary angiodema treatment Firazyr (icatibant) will not undergo a review by FDA's Pulmonary-Allergy Drugs Advisory Committee, the firm says Jan. 8. The panel was scheduled to meet Feb. 20 to discuss the orphan drug candidate, which has an April 26 user fee date under priority review...